Raymond James Financial Services Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Raymond James Financial Services Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-116,423	Closed	-$2.98M	–	3349
2023 Q3	$2.98M	Sell	116,423 -6,518	-5%	-$172K	0.01%	1283
2023 Q2	$3.22M	Sell	122,941 -349	-0.3%	-$9.22K	0.01%	1253
2023 Q1	$3.22M	Buy	123,290 +19,295	+19%	+$517K	0.01%	1220
2022 Q4	$2.85M	Buy	+103,995	New	+$2.77M	0.01%	1244

Other funds holding FTXH

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Glenview Trust Louisville, Kentucky $6.37B AUM 23.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

OWA

Outlook Wealth Advisors Shenandoah, Texas $413M AUM 19.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial Services Advisors's FTXH Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q4 2023, closing a stake of 116,423 shares — an estimated $2.98M sold.

Raymond James Financial Services Advisors first reported a position in FTXH in Q4 2022 and held it in 4 quarters. The position peaked at $3.22M in Q2 2023. 22 funds tracked by Wall St. Rank hold FTXH as of Q4 2023.

Raymond James Financial Services Advisors reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q4 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 116,423 First Trust Nasdaq Pharmaceuticals ETF shares in Q4 2023, an estimated $2.98M.
Raymond James Financial Services Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and held it in 4 quarters.
Raymond James Financial Services Advisors's First Trust Nasdaq Pharmaceuticals ETF position peaked at $3.22M in Q2 2023.
22 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.